The Cancer Letter

Inside information on cancer research and drug development

In Brief

St. Jude to Open Grad School for Biomedical Sciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ST. JUDE CHILDREN’S RESEARCH HOSPITAL has received a unanimous vote of approval from the Tennessee Higher Education Commission for the opening of a new graduate school of biomedical sciences.

Stephen White, a faculty member in the St. Jude Department of Structural Biology, will serve as dean of the graduate school. The school will be located in the Marlo Thomas Center for Global Education and Collaboration, and will welcome the inaugural class in fall 2017.

“The graduate school will play an important role in our research efforts to advance cures for pediatric catastrophic diseases,” said James Downing, St. Jude president and CEO, “Talented graduate students are a creative and energetic force that will contribute to the kind of innovation required for progress against cancer and other life-threatening diseases. These students will ask the unexpected questions, challenge fundamental assumptions and will help tackle the most difficult scientific problems.”

Students will also interact with the neighboring University of Tennessee Health Science Center and Le Bonheur Children’s Hospital.

Table of Contents

YOU MAY BE INTERESTED IN

Obituary

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
By Melinda Krigel
Obituary

Feng’s team advanced the understanding of biomarkers in prostate cancer

The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.
By NRG Staff
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account